We are now… CENEXEL
On June 16, 2022, Apex Innovative Sciences, parent company of Hassman Research Institute (HRI) and Collaborative Neuroscience Research (CNS), was acquired by CenExel Clinical Research.
CenExel now comprises 19 of the most proficient, therapeutically-focused, wholly-owned clinical research sites in the country, with special emphases on Psychiatry, Neurology, Pain, Human Abuse Liability, Vaccines/Immunology, Dermatology, Ethnic Bridging, Sleep, and Clinical Pharmacology/Phase I. On a combined basis, CenExel’s clinical research units have more than 500 inpatient beds with the ability to perform both simple and highly complex early phase trials. Each of the CenExel Centers of Excellence units has an outstanding track record of assisting pharmaceutical sponsors with protocol development, study design, and conduct in Phase I-IV trials to develop new therapeutics for improved patient care.
For more information, please visit www.cenexel.com